ADAP
Adaptimmune Therapeutics
ADAP
ADAP
86 hedge funds and large institutions have $663M invested in Adaptimmune Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
5% more capital invested
Capital invested by funds: $631M → $663M (+$32.9M)
0.11% less ownership
Funds ownership: 9.99% → 9.88% (-0.11%)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
Holders
86
Holding in Top 10
5
Calls
$2.08M
Puts
$654K
Top Buyers
| 1 | +$6.98M | |
| 2 | +$5.55M | |
| 3 | +$4.68M | |
| 4 |
BAMCO Inc
New York
|
+$4.1M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$3.56M |
Top Sellers
| 1 | -$7.49M | |
| 2 | -$7.46M | |
| 3 | -$4.78M | |
| 4 |
QF
QVT Financial
New York
|
-$4.12M |
| 5 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$4M |